KL264-01

· Klus Pharma Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KL264-01, covering 2025-05-20 to 2025-05-20. Get the full timeline:

Most recent: Clinical Trial Update: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) [Phase 1, Phase 2]

See pricing